

29th July 2026

The Manager-Listing
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

the Manager- Listing
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra-Kurla Complex
Bandra (E)
Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Sub - Outcome of Board Meeting.

Ref – Regulation 30 and Regulation 33 and Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements).

We inform you that the Board of Directors of the Company, at its Meeting held today i.e. on Wednesday, 29th July 2026, has approved the following.

Pursuant to above-referred regulations, we enclose the following documents.

1. Statement of unaudited Standalone financial results, for the quarter ended 30th June 2026. (Annexure-I).
2. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure-II).
3. Statement of unaudited Consolidated financial results, for the quarter ended 30th June 2026. (Annexure-III).
4. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure-IV).
5. Approved and fix the date of 33rd Annual General Meeting of the Company to be held on Thursday, 24th September 2026 at 11:00 a.m. through video conference/other audio-visual means accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India.

The procedure for participation in the Annual General Meeting and book closure and record date will be intimated separately.

The Meeting Commenced on 01:00 p.m. and concluded on 04:00 p.m.

You are requested to take the above information on record.

Thanking You

Yours faithfully,
For Nath Bio-Genes (India) Limited,

Amol Gupta
Chief Financial Officer



Nath Bio-Genes (I) Ltd.

(CIN L01110MH1903PLC072842)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND 3 MONTHS ENDED 30/06/2026

Rs in Lakhs

SR. No.	Particulars	Quarter Ended			Three Months Ended		Year Ended
		30-06-2026 Unaudited	31-03-2026 Audited	30-06-2025 Unaudited	30-06-2026 Unaudited	30-06-2025 Unaudited	31-03-2026 Audited
I	Income from operations						
	(a) Revenue from operations	32284.28	4569.36	28017.18	32284.28	28017.18	43159.72
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income	32284.28	4569.36	28017.18	32284.28	28017.18	43159.72
II	Expenses						
	a) Production & Seed Conditioning Expenses	11001.14	6770.30	10824.23	11001.14	10824.23	29768.84
	b) Purchase of Stock-in-Trade	122.90	186.99	435.33	122.90	435.33	752.09
	c) Change in Inventories of Produced and Traded Goods	4875.21	(5661.54)	2379.62	4875.21	2379.62	(11388.72)
	d) Employee Benefit Expense	1036.03	347.86	905.17	1036.03	905.17	3333.33
	e) Depreciation & Amortisation Expenses	100.50	102.29	97.50	100.50	97.50	394.79
	f) Selling & Distribution Expenses	10797.45	1400.93	9569.91	10797.45	9569.91	12177.26
	g) Other Expenses	944.06	863.57	912.69	944.06	912.69	3263.29
	Total Expenses	28877.29	4010.39	25124.44	28877.29	25124.44	38300.88
III	Profit from Operations before other income, finance cost and Exceptional Items (I-II)	3406.99	558.97	2892.74	3406.99	2892.74	4858.84
IV	Other Income	190.05	237.50	176.45	190.05	176.45	781.00
V	Profit from Ordinary Activities before Finance cost and Exceptional Items (III+IV)	3597.04	796.47	3069.19	3597.04	3069.19	5639.84
VI	Finance Cost	379.25	293.51	288.96	379.25	288.96	1330.69
VII	Profit from Ordinary Activities after Finance cost (V-VI)	3217.79	502.96	2780.23	3217.79	2780.23	4309.15
VIII	Exceptional Items Income/(Expenses)	119.98	125.79	206.34	119.98	206.34	600.73
IX	Profit from Ordinary Activities before Tax (VII-VIII)	3337.77	628.75	2986.57	3337.77	2986.57	4909.88
X	Tax Expense						
	(a) Current Tax	72.09	233.06	65.97	72.09	65.97	450.42
	(b) Earlier Year Tax	0.00	16.89	0.00	0.00	0.00	16.89
	(c) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
XI	Net Profit from Ordinary Activities after Tax (IX-X)	3265.68	378.80	2920.60	3265.68	2920.60	4442.57
XII	Extra Ordinary Items (Net of Tax)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Net Profit for the period (XI-XII)	3265.68	378.80	2920.60	3265.68	2920.60	4442.57
XIV	Other Comprehensive Income						
	1. (a) Items that will not be reclassified to Profit or Loss	(1.75)	0.73	(1.50)	(1.75)	(1.50)	(4.17)
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	2. (a) Items that will be reclassified to Profit or Loss	4.00	32.99	(6.50)	4.00	(6.50)	11.99
	(b) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	Total other Comprehensive Income	2.25	33.72	(8.00)	2.25	(8.00)	7.82
XV	Total Comprehensive Income for the period (XIII + XIV)	3267.93	412.52	2912.60	3267.93	2912.60	4450.39
XVI	Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1900.40	1900.40	1900.40	1900.40	1900.40	1900.40
XVII	Reserve & Surplus						67036.62
XVIII	Earning per share (of Rs 10/- each) (not annualised) Basic & Diluted	17.18	1.99	15.37	17.18	15.37	23.38

Notes: Please refer attached sheet

FOR GAUTAM N ASSOCIATES

CHARTERED ACCOUNTANTS

GAUTAM NANDAWAT
(Partner)


UDIN:-26032942ZKBEJO1220

Place : Chhatrapati Sambhajnagar

Date :29 July 2026

SATISH KAGLIWAL
MANAGING DIRECTOR
DIN 00119601

Regd. Office : Nath House, Nath Road, Chhatrapati Sambhajnagar - 431005 (MS)
www.nathbiogenes.com



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)



**NOTES TO UNAUDITED STANDALONE RESULTS FOR THE QUARTER & 3 MONTHS
ENDED ON 30/06/2026**

1. The financial results were reviewed by the Audit Committee on 28 July 2026 and were thereafter approved by the Board of Directors at its meeting held on 29 July 2026.
2. The short provision of Schemes of Rs. 900.00 Lakhs pertaining to the quarter ending June 2025, as reported in the quarterly results of March 26 is now considered and represented in the results of June 2025.
3. The company deals with only one major product segment of Seed Cultivation. Thus, segmental reporting is not provided.
4. Investor Complaints:
 - a. Received during the quarter - NIL
 - b. Pending at the end of quarter – NIL
5. The figures have been regrouped/rearranged, wherever necessary.

**FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS**

Gautam
GAUTAM NAWAWAT
(Partner)

UDIN: 26032742ZKBE101220



Satish
Satish Kagliwal
Managing Director
DIN: 00119601

Place: Chhatrapati Sambhaji Nagar
Date: 29 July 2026



INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED STANDLONE IND-AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED

To,
The Board of Directors
Nath Bio-Genes (India) Limited
Chhatrapati Sambhajinagar (Aurangabad)


1. We have reviewed the accompanying standalone statement of unaudited financial results of **Nath Bio-Genes (India) Limited (CIN : L01110MH1993PLC072842)** for the quarter ended 30th June 2026 and year to date results for the period 1st April 2026 to 30th June 2026 ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.

2. This standalone statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.

3. We conducted our review of the standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the standalone financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying standalone statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has, except as mentioned in para 5 below in the Basis for qualified opinion, not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gautam N Associates
Chartered Accountants
FRN: 103117W


Gautam Nandawat
Partner

M No: 032742

UDIN: 26032742ZKBEJO1220



Place: Chhatrapati Sambhajinagar
Date: 29th July 2026



Nath Bio-Genes (I) Ltd.

(CIN L01110MH11003PLC072042)

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND 3 MONTHS ENDED 30/06/2026

Rs in Lakhs


SR. No.	Particulars	Quarter Ended			Three Months Ended		Year Ended
		30-06-2026 Unaudited	31-03-2026 Audited	30-06-2025 Unaudited	30-06-2026 Unaudited	30-06-2025 Unaudited	31-03-2026 Audited
I	Income from operations						
	(a) Revenue from operations	32840.42	5159.28	28370.01	32840.42	28370.01	44510.15
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income	32840.42	5159.28	28370.01	32840.42	28370.01	44510.15
II	Expenses						
	a) Production & Seed Conditioning Expenses	11449.16	6920.21	10885.18	11449.16	10885.18	30618.01
	b) Purchase of Stock-in-Trade	122.90	204.88	435.33	122.90	435.33	769.98
	c) Change in Inventories of Produced and Traded Goods	4907.87	(5545.29)	2661.88	4907.87	2661.88	(11237.58)
	d) Employee Benefit Expense	1082.00	420.71	959.27	1082.00	959.27	3579.27
	e) Depreciation & Amortisation Expenses	100.50	102.68	97.50	100.50	97.50	396.42
	f) Selling & Distribution Expenses	10810.44	1866.84	9569.91	10810.44	9569.91	12243.17
	g) Other Expenses	953.00	844.23	930.05	953.00	930.05	3293.43
	Total Expenses	29425.87	4814.24	25539.12	29425.87	25539.12	39662.70
III	Profit from Operations before other income, finance cost and Exceptional Items (I-II)	3414.55	345.04	2830.89	3414.55	2830.89	4847.45
IV	Other Income	190.05	237.50	176.45	190.05	176.45	781.00
V	Profit from Ordinary Activities before Finance cost and Exceptional Items (III+IV)	3604.60	582.54	3007.34	3604.60	3007.34	5628.45
VI	Finance Cost	426.31	459.28	319.61	426.31	319.61	1598.84
VII	Profit from Ordinary Activities after Finance cost (V-VI)	3178.29	123.27	2687.74	3178.29	2687.74	4029.61
VIII	Exceptional Items Income/(Expenses)	119.98	125.80	206.34	119.98	206.34	600.74
IX	Profit from Ordinary Activities before Tax (VII-VIII)	3298.27	249.07	2894.08	3298.27	2894.08	4630.35
X	Tax Expense						
	(a) Current Tax	72.09	233.06	65.97	72.09	65.97	450.42
	(b) Earlier Year Tax	0.00	16.90	0.00	0.00	0.00	16.90
	(c) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
XI	Net Profit from Ordinary Activities after Tax (IX-X)	3226.18	(0.89)	2828.11	3226.18	2828.11	4163.03
XII	Extra Ordinary Items (Net of Tax)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Net Profit for the period (XI-XII)	3226.18	(0.89)	2828.11	3226.18	2828.11	4163.03
XIV	Other Comprehensive Income						
	1. (a) Items that will not be reclassified to Profit or Loss	(1.75)	(182.86)	(1.50)	(1.75)	(1.50)	(187.76)
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	2. (a) Items that will be reclassified to Profit or Loss	4.00	32.99	(6.50)	4.00	(6.50)	11.99
	(b) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	Total other Comprehensive Income	2.25	(149.87)	(8.00)	2.25	(8.00)	(175.77)
XV	Total Comprehensive Income for the period (VII + VIII)	3228.43	(150.76)	2820.11	3228.43	2820.11	3987.26
XVI	Share in Profit / (Loss) of minority share holder	0.00	0.00	0.00	0.00	0.00	0.00
XVII	Profit related to Holding Company	3228.43	(150.76)	2820.11	3228.43	2820.11	3987.26
XVI	Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1900.40	1900.40	1900.40	1900.40	1900.40	1900.40
XVII	Reserve & Surplus						66145.48
XVI	Earning per share (of Rs 10/- each) (not annualised) Basic & Diluted	16.98	(0.00)	14.88	16.98	14.88	21.91

Notes: Please refer attached sheet

FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS


GAUTAM NANDAWAT
(Partner)

UDIN:-26032742HJMMUT5489




FOR NATH BIO-GENES (INDIA) LTD

SATISH KAGLIWAL
MANAGING DIRECTOR
DIN 00119601



Place : Chhatrapati Sambhajinagar

Date :29 July 2026



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)



**NOTES TO CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER & 3 MONTHS
ENDED ON 30/06/2026**

1. The financial results were reviewed by the Audit Committee on 28 July 2026 and were thereafter approved by the Board of Directors at its meeting held on 29 July 2026.
2. The results have been consolidated with Nath Bio-Genes CA, Uzbekistan, where in the company is holding 90% of equity.
3. The short provision of Schemes of Rs. 900.00 Lakhs pertaining to the quarter ending June 2025, as reported in the quarterly results of March 26 is now considered and represented in the results of June 2025.
4. The company deals with only one major product segment of Seed Cultivation. Thus, segmental reporting is not provided.
5. Investor Complaints:
 - a. Received during the quarter - NIL
 - b. Pending at the end of quarter – NIL
6. The figures have been regrouped/rearranged, wherever necessary.

**FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS**

Satish
GAUTAM NANDAWAT
(Partner)

UDIN:- 26032742HJMMUT5489



Satish
Satish Kagliwal
Managing Director
DIN: 00119601

Place: Chhatrapati Sambhaji Nagar
Date: 29 July 2026



Gautam N Associates

Chartered Accountants

30, GNA House, Behind ABC Complex,
Manmandir Travels Lane, Adalat Road, Aurangabad - 431 001

Independent Auditor's Review Report on consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors
Nath Bio-Genes (India) Limited
Chhatrapati Sambhajinagar (Aurangabad)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Nath Bio-Genes (India) Limited** (CIN: L01110MH1993PLC072842) ("the Parent") and its joint venture company (the Parent and its joint venture company together referred to as "the Group"), and its share of the net loss of its joint venture company for the quarter ended 30th June 2026 and for the period from 1st April 2026 to 30th June 2026 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

A Joint Venture Entity is located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles generally accepted in its country. The Unaudited Financial Statements of Joint Venture entity have been considered as authenticated by its management for the purpose of consolidation. The Parent Company's management has converted these financial statements of such joint venture located outside India from accounting principles generally accepted in its country to accounting principles generally accepted in India (Ind AS).

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the Nath Bio-Genes (Central Asia) LLC., Uzbekistan a joint venture company.



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has, except as mentioned in para 6 below in the Basis for qualified opinion, not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gautam N Associates
Chartered Accountants
FRN: 103117W


Gautam Nandawat
Partner
M No: 032742
UDIN: 26032742HJMMUT5489



Place: Chhatrapati Sambhajinagar
Date: 29th July 2026